This invention can aid in the development of novel CAV2.2 targeted medications with improved efficacy as an alternative to opioids with novel compound binds to Cavβ2a and Cav2.2.

About

Calcium Channel Antagonist for Pain

Tech ID: UA16-139

Invention:
This novel compound binds to Cavβ2a, which inhibits calcium influx, selectively inhibits N-type calcium channels (Cav2.2), and can aid in the development of novel CAV2.2 targeted medications with improved efficacy as an alternative to opioids.

Background:
Currently, the growing U.S. non-opioid pain management pharmaceuticals market has an opportunity to introduce novel therapeutics with improved side effect profiles, compared to those of opioids, without the ease of abuse. For example, hyperexcitability of sensory neurons from aberrant calcium signaling can result in certain pain conditions and research has shown that accumulation of inactivated CAV2.2 is associated with decreased calcium influx. As stated above, this technology has the potential to aid in the development of CAV2.2 targeted medications with the intent to act as a substitute for opioids in pain relief.

Key Benefits

- The first small molecule to bind to the beta subunit of the Cav alpha-beta interaction
- Results in less problematic side effects and difficult dosing regimens
- Fills an unmet need for novel CAV2.2-targeted medications
- Improves efficacy
- Acts as an alternative to opioids

Applications

- Treatment of chronic and acute pain
- Treatment of cardiovascular disorders associated with abnormal calcium balance
- Treatment of neurological disorders associated with abnormal calcium balance

Purchase a license for full unlimited access to all innovation profiles on LEO

  • Direct connection to thousands of more innovations
  • Access to market Experts and Universities
  • Filter relevant solutions into your own dedicated Network